PMC5385905_01
Liver enzymes and HBV tests in relation to chemotherapy, autologous stem cell transplant, and entecavir therapy.
CRIHEP2017-2463953.001.jpg
PMC5385905_01_CRIHEP2017-2463953.001.jpg
fig1
His anti-HCV was negative and he remained immune to hepatitis A. In retrospect, liver enzymes had been abnormal (ALT peak 182) during the HBV vaccination period but were normal when his wife presented with acute hepatitis (see Figure 1). An abdominal ultrasound was unremarkable and a FibroScan was consistent with F1 (minimal) fibrosis. He was started immediately on entecavir for HBV reactivation.
PMC5385905_02
Liver enzymes and HBV tests in relation to entecavir therapy.
CRIHEP2017-2463953.002.jpg
PMC5385905_02_CRIHEP2017-2463953.002.jpg
fig2
Blood tests showed marked transaminitis (see Figure 2), INR 1.3, and Bilirubin up to 411 umol/L.